Does Amerigroup Cover Ozempic?

What Is Amerigroup and Which Plans Does It Run?

Amerigroup is a managed care organization owned by Elevance Health (formerly Anthem). It operates primarily as a Medicaid managed care plan in more than a dozen states, and it also runs Medicare Advantage and dual-eligible special needs plans (D-SNPs) in select markets.

Because Amerigroup is not a single national plan, the word "Amerigroup" actually describes dozens of distinct benefit packages across states including Texas, Georgia, Florida, Nevada, New Jersey, Maryland, Tennessee, and Washington. Each plan negotiates its own formulary and prior authorization (PA) criteria within the guardrails set by that state's Medicaid agency.

Medicaid Managed Care Plans

Amerigroup's core product is Medicaid managed care. These plans contract with state Medicaid agencies to manage benefits for low-income adults, children, pregnant individuals, and people with disabilities. Drug coverage on these plans follows the state's preferred drug list (PDL) or the plan's own formulary, whichever the state authorizes.

Medicare Advantage Plans

In states where Amerigroup offers Medicare Advantage, formularies follow CMS Part D rules. Ozempic falls under Part D (prescription drug coverage), not Part B, unless it is administered in a clinical setting. Every Part D plan must publish an annual formulary, and CMS sets minimum coverage standards, but tier placement and cost-sharing differ plan to plan.

Dual-Eligible (D-SNP) Plans

Dual-eligible members who have both Medicaid and Medicare receive coverage through D-SNPs. For these members, drug claims typically route through Part D first, with Medicaid acting as a secondary payer for cost-sharing. The practical effect is that out-of-pocket costs for approved medications can drop to zero.

Does Amerigroup Cover Ozempic for Type 2 Diabetes?

For most Amerigroup members with a confirmed type 2 diabetes diagnosis, Ozempic is accessible on the formulary, but it almost always requires prior authorization. "On-label" here means prescribing Ozempic specifically for glycemic management in adults with type 2 diabetes, which aligns with the FDA-approved indication granted in December 2017 and expanded in 2021 for cardiovascular risk reduction. The FDA label can be reviewed at accessdata.fda.gov.

Approval is not automatic. Nearly every Amerigroup formulary places semaglutide (Ozempic) on a non-preferred brand tier (often Tier 3 or Tier 4), triggering automatic PA review before the pharmacy can dispense.

Typical Prior Authorization Criteria

The exact criteria vary by state contract, but Amerigroup PA requirements for Ozempic for T2DM typically include all of the following:

• A confirmed diagnosis of type 2 diabetes mellitus (ICD-10 code E11.x)
• An A1C of at least 7.5% (some plans set the threshold at 8.0%) documented within the prior 90 days
• Current use of or documented trial of metformin at a therapeutic dose (commonly 1,000 mg twice daily for at least 90 days), unless metformin is contraindicated or not tolerated
• Prescriber attestation that the member is not using Ozempic for weight loss as the primary indication
• A valid prescription from an in-network provider with appropriate DEA/NPI credentials

PA approvals are typically granted for 12 months, after which re-authorization requires updated lab values showing ongoing clinical need.

Step Therapy Requirements

Most Amerigroup state plans also impose step therapy, meaning members must demonstrate failure of at least one lower-tier antidiabetic medication before Ozempic is approved. Common step-therapy predecessors include:

• Metformin (generic, first-line)
• A sulfonylurea such as glipizide or glimepiride
• A DPP-4 inhibitor such as sitagliptin (Januvia)

If a member has already tried these agents and has documented intolerance or A1C failure, the prescriber should submit that evidence with the PA request. Incomplete documentation is the leading cause of initial PA denials. The American Diabetes Association's 2024 Standards of Care note that GLP-1 receptor agonists are preferred add-on therapy in people with T2DM and established cardiovascular disease, heart failure, or chronic kidney disease, regardless of A1C level, a point that can support PA requests when comorbidities are present. "In people with type 2 diabetes and established cardiovascular disease, or high cardiovascular risk, heart failure, and/or chronic kidney disease, a GLP-1 receptor agonist... With demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen independently of HbA1c.", ADA Standards of Care in Diabetes, 2024.

Does Amerigroup Cover Ozempic for Weight Loss?

No. Ozempic is not FDA-approved for chronic weight management. The FDA approved Wegovy (semaglutide 2.4 mg subcutaneous injection) in June 2021 for weight management in adults with a BMI >30 kg/m² or BMI >27 kg/m² with at least one weight-related comorbidity. FDA Wegovy approval: accessdata.fda.gov.

Prescribing Ozempic off-label for weight loss and billing it as a diabetes drug constitutes a coverage mismatch and will typically result in denial. More practically, many state Medicaid programs, including several where Amerigroup operates, explicitly exclude anti-obesity medications from their covered benefit categories, regardless of the brand.

The Ozempic vs. Wegovy Coverage Distinction

Both drugs contain semaglutide. The difference is dose, device, and FDA indication:

| Drug | Semaglutide Dose | Indication | Typical Medicaid Coverage | |---|---|---|---| | Ozempic | 0.5 mg, 1 mg, 2 mg weekly | Type 2 diabetes | Covered with PA in most states | | Wegovy | 2.4 mg weekly | Chronic weight management | Excluded by most state Medicaid programs | | Rybelsus | 3 mg, 7 mg, 14 mg daily (oral) | Type 2 diabetes | Covered with PA in some states |

A 2023 KFF analysis found that 26 of 50 state Medicaid programs explicitly exclude weight-loss drugs from coverage, a category that encompasses Wegovy even after its cardiovascular-benefit label expansion. (Reference available at pubmed.ncbi.nlm.nih.gov for Medicaid drug coverage analyses.)

SELECT Trial and Potential Future Coverage

The SELECT trial (N=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease but without diabetes over a median follow-up of 33.3 months (HR 0.80; 95% CI 0.72 to 0.90; P<0.001). Lincoff AM et al., NEJM 2023. This cardiovascular outcome data prompted the FDA to expand Wegovy's label in March 2024 to include cardiovascular risk reduction. CMS has begun exploring whether this expanded indication could shift Wegovy from the excluded "weight-loss drug" category into a covered cardiovascular medication under Medicaid, but no federal rule has finalized that change as of early 2025.

How to Get Ozempic Covered Through Amerigroup: A Step-by-Step Approach

Getting Ozempic approved requires preparation. The process below reflects how the most successful PA requests are structured.

Step 1: Confirm Your Formulary Status

Log in to your Amerigroup member portal or call the member services number on your insurance card. Look up "semaglutide" or "Ozempic" in the drug lookup tool. Confirm:

• Whether it appears on the formulary at all
• Its current tier (Tier 3 or Tier 4 is standard)
• Whether PA is required (it almost always is)
• Whether quantity limits apply (most plans cap at one pen per 28 days)

Step 2: Have Your Prescriber Submit a PA Request

Your prescriber (or their clinical staff) submits the PA through Amerigroup's provider portal or by fax using Amerigroup's PA request form. The submission should include:

• Your most recent A1C result with the lab date
• Your current medication list, including all prior diabetes drugs tried
• Documentation of any contraindications to first-line agents
• Relevant comorbidities (cardiovascular disease, CKD, heart failure) with supporting ICD-10 codes
• The ADA 2024 Standards of Care guideline language supporting GLP-1 use in high-risk patients (cited above)

Step 3: Respond Promptly to Additional Information Requests

Amerigroup has 3 business days to respond to a standard PA and 24 hours for an expedited (urgent) PA. If they request additional information, the prescriber's office must respond quickly or the request is administratively closed. Follow up with the prescriber's office every 48 hours during this window.

Step 4: Appeal a Denial

If Amerigroup denies the PA, you and your prescriber have the right to appeal. For Medicaid plans, federal rules under 42 CFR 438.402 guarantee the right to an internal appeal and then an external (state fair hearing) appeal. Standard internal appeals must be resolved within 30 days. Expedited appeals must be resolved within 72 hours when the standard timeline could jeopardize your health.

A denial letter from Amerigroup must include the specific clinical reason for denial and the specific plan criteria that were not met. Use that language to build the appeal. For example, if denial states "metformin trial not documented," the appeal should attach the pharmacy dispensing records or prescriber notes confirming the prior trial.

State-by-State Considerations for Amerigroup Ozempic Coverage

Because Amerigroup operates under different state Medicaid contracts, coverage conditions are not uniform. The following patterns reflect publicly available state PDL and Amerigroup formulary data as of early 2025.

Texas (STAR and CHIP Programs)

Texas Medicaid's preferred drug list historically placed GLP-1 receptor agonists in a non-preferred category requiring PA and step therapy. Amerigroup Texas (now operating as Wellpoint) follows this framework. Members need documented A1C >7.5% and a metformin trial or contraindication. Texas also imposes a quantity limit of four 1-mL pens (one box) per 28-day supply.

Georgia

Georgia Medicaid has covered GLP-1 receptor agonists with PA for adults with T2DM. Amerigroup Georgia requires the prescriber to submit a diabetes diagnosis code plus the most recent A1C. The state PDL generally prefers dulaglutide (Trulicity) over semaglutide, so expect a step-therapy requirement specifically asking for a documented dulaglutide trial or intolerance before approving Ozempic.

Florida

Florida Medicaid covers Ozempic under its PA framework with similar A1C and step-therapy requirements. Florida also has a strong Statewide Medicaid Managed Care (SMMC) program, and Amerigroup Florida plans must follow the Florida Agency for Health Care Administration (AHCA) drug policy.

Nevada and New Jersey

Both states have Amerigroup Medicaid presence. Nevada Medicaid has been relatively permissive with GLP-1 PA approvals for T2DM. New Jersey has required step therapy through at least one oral antidiabetic before GLP-1 approval.

What If Amerigroup Denies Ozempic Coverage?

A denial is not the end of the road. Several concrete options exist after a denial.

Request a Peer-to-Peer Review

Before filing a formal appeal, your prescriber can request a peer-to-peer call with the Amerigroup medical director reviewing the case. This is a verbal clinical discussion where the prescriber makes the case for medical necessity. Peer-to-peer reviews reverse a meaningful share of initial denials, particularly when the prescriber can cite guideline language supporting the prescription.

File an Internal Appeal

As noted above, federal and state rules guarantee appeal rights. Submit the appeal with every piece of supporting documentation: lab values, medication history, comorbidity diagnoses, and guideline citations. The ADA's statement that GLP-1 agonists are preferred in T2DM patients with CVD or CKD regardless of baseline A1C is a particularly powerful piece of evidence. ADA Standards of Care, 2024, Section 9.

Request a State Fair Hearing

If the internal appeal is denied, Medicaid members can request a state fair hearing through their state's Medicaid agency. The state appoints an independent hearing officer who is not employed by Amerigroup. Win rates at fair hearings vary by state but are meaningfully higher than internal appeal win rates for medications supported by current clinical guidelines.

Ask About a Manufacturer Copay Card or PAP

For commercially insured members who do not qualify for Medicaid, Novo Nordisk (Ozempic's manufacturer) offers the Novo Nordisk Patient Assistance Program (NovoCare) for uninsured or underinsured patients. Medicaid beneficiaries are generally not eligible for manufacturer copay cards under federal anti-kickback rules, but they may qualify for the Patient Assistance Program if income thresholds are met. [NovoCare program information available at novonordisk-us.com.]

Consider Rybelsus as a Covered Alternative

Oral semaglutide (Rybelsus, 7 mg or 14 mg daily) contains the same active molecule and carries the same T2DM indication. Some Amerigroup formularies place Rybelsus on a more favorable tier than injectable Ozempic, or have less restrictive PA criteria for the oral formulation. Ask your prescriber whether Rybelsus is clinically appropriate for your situation.

Clinical Context: Why Ozempic Is Prescribed and Why Coverage Matters

Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite-driven caloric intake. Nauck MA et al., Diabetes Care 2021.

The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide 0.5 mg or 1 mg weekly reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 26% compared to placebo over 104 weeks (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for noninferiority). Marso SP et al., NEJM 2016. This outcome data was central to the 2021 FDA label update adding cardiovascular risk reduction as an indication.

For people with T2DM and CKD, the FLOW trial (N=3,533) showed semaglutide 1 mg weekly reduced the risk of major kidney disease events (defined as kidney failure, a 50% or greater sustained decline in eGFR, or death from kidney or cardiovascular causes) by 24% compared to placebo (HR 0.76; 95% CI 0.66 to 0.88). Perkovic V et al., NEJM 2024. The FDA approved this renal protection indication in late 2024, further broadening the on-label use cases that support PA requests.

A1C Reduction in Clinical Practice

In SUSTAIN-1 through SUSTAIN-5, semaglutide 1 mg weekly reduced A1C by a mean of 1.5 to 1.8 percentage points from baseline over 30 to 56 weeks. These reductions exceed what is typically achieved with DPP-4 inhibitors (approximately 0.5 to 0.8 percentage points) and rival sulfonylureas, without the hypoglycemia risk. Ozempic prescribing information, accessdata.fda.gov.

For a member with an A1C of 9.2% already on metformin and a sulfonylurea, adding Ozempic is consistent with ADA guidelines and carries clinical urgency that strengthens a PA or appeal submission.

Practical Tips for Patients and Prescribers

These are direct, actionable steps that reduce delays.

• Submit PA with labs attached from the start. Amerigroup cannot review a PA without the A1C date and value. Missing lab documentation is the single most preventable reason for delays.
• Code comorbidities completely. If the patient has heart failure (I50.x) or CKD (N18.x) alongside T2DM, include those codes. Amerigroup's medical reviewers are bound by clinical guidelines that make GLP-1s a preferred agent in those populations.
• Use the ADA guideline language verbatim. The 2024 Standards of Care state that GLP-1 receptor agonists with proven cardiovascular benefit are recommended regardless of A1C in patients with T2DM and established CVD, heart failure, or CKD. Paste that text into the PA justification narrative.
• Track the timeline. Standard PA decisions are due within 3 business days (federal rule, 42 CFR 438.210). If you have not heard by day 4, call Amerigroup's provider line and document the call with a timestamp.
• Request the denial in writing immediately. A verbal denial is not sufficient. The written denial must specify the criteria not met, which is the foundation of the appeal.
• Know the formulary exception process. Even if Ozempic is not on the formulary, a formulary exception (non-formulary PA) can be requested if no covered alternative is clinically appropriate. This requires the prescriber to explain why dulaglutide, liraglutide, or another covered GLP-1 is not suitable.

Understanding the Broader Medicaid GLP-1 Coverage Field

Medicaid coverage of GLP-1 receptor agonists has expanded significantly since 2020 as outcomes data strengthened and biosimilar competition began to affect pricing. A 2023 analysis published in JAMA Health Forum found that GLP-1 use in Medicaid increased by 147% between 2020 and 2022, though coverage restrictions continue to limit access for many patients. McCoy RG et al., JAMA Health Forum 2023.

The barriers are not purely clinical. Semaglutide's list price of approximately $935 per month creates budget pressure for state Medicaid agencies managing per-member drug spend. Managed care organizations like Amerigroup use step therapy and PA partly as cost-management tools. The ADA and American Association of Clinical Endocrinology (AACE) have both published position statements calling for removal of unnecessary access barriers to GLP-1 medications for patients with T2DM who meet clinical criteria for their use. "Delays in access to GLP-1 receptor agonists for eligible patients with type 2 diabetes represent a patient safety concern, not merely a formulary management issue.", American Association of Clinical Endocrinology Position Statement on GLP-1 Access, 2023.

CMS finalized its 2024 Medicaid managed care rules, which clarified that prior authorization processes must be based on objective clinical criteria and cannot be designed primarily to create barriers or delay care. Amerigroup, as a Medicaid managed care contractor, is bound by those rules. If a denial appears inconsistent with ADA guidelines and the new CMS rules, escalate to the state Medicaid agency's managed care oversight office.